Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
Mol Neurobiol ; 53(3): 1661-1671, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25687432

RESUMEN

In this study, we investigated the neuroprotective effect of sevoflurane against ischemic brain injury and its underlying molecular mechanisms. Transient global brain ischemia was induced by 4-vessel occlusion in adult male Sprague-Dawley rats. The rats were pretreated with sevoflurane alone or sevoflurane combined with LY294002/wortmannin (selective inhibitor of PI3K) before ischemia. Cresyl violet staining was used to examine the survival of hippocampal CA1 pyramidal neurons. Immunoblotting and immunoprecipitation were performed to measure the phosphorylation of Akt1, PRAS40, ASK1, and JNK3 and the expression of cleaved-caspase-3. The results demonstrated that a moderate dose of sevoflurane inhalation of 2% for 2 h had significant neuroprotective effects against ischemia/reperfusion induced hippocampal neuron death. Sevoflurane significantly increased Akt and PRAS40 phosphorylation and decreased the phosphorylation of ASK1 at 6 h after reperfusion and the phosphorylation of JNK3 at 3 days after reperfusion following 15 min of transient global brain ischemia. Conversely, LY294002 and wortmannin significantly inhibited the effects of sevoflurane. Taken together, the results suggest that sevoflurane could suppress ischemic brain injury by downregulating the activation of the ASK1/JNK3 cascade via increasing the phosphorylation of Akt1 during ischemia/reperfusion.


Asunto(s)
Lesiones Encefálicas/tratamiento farmacológico , Caspasa 3/metabolismo , Éteres Metílicos/uso terapéutico , Proteína Quinasa 10 Activada por Mitógenos/metabolismo , Neuroprotección/efectos de los fármacos , Daño por Reperfusión/tratamiento farmacológico , Daño por Reperfusión/enzimología , Androstadienos/farmacología , Androstadienos/uso terapéutico , Animales , Apoptosis/efectos de los fármacos , Lesiones Encefálicas/complicaciones , Lesiones Encefálicas/enzimología , Lesiones Encefálicas/patología , Región CA1 Hipocampal/efectos de los fármacos , Región CA1 Hipocampal/patología , Cromonas/farmacología , Cromonas/uso terapéutico , Activación Enzimática/efectos de los fármacos , MAP Quinasa Quinasa Quinasa 5/metabolismo , Masculino , Éteres Metílicos/farmacología , Modelos Biológicos , Morfolinas/farmacología , Morfolinas/uso terapéutico , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Neuronas/patología , Fármacos Neuroprotectores/farmacología , Fosforilación/efectos de los fármacos , Ratas Sprague-Dawley , Daño por Reperfusión/complicaciones , Daño por Reperfusión/patología , Sevoflurano , Transducción de Señal/efectos de los fármacos , Wortmanina
2.
Am J Med Sci ; 347(5): 343-6, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-23689047

RESUMEN

OBJECTIVES: The aim of this study was to study the effect of oxygen-driven nebulization (ODN) at different oxygen flows on heart rate, respiratory rate, SpO2, SaO2, PaO2, PaCO2 and pH of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients. METHODS: According to random number table, 9 AECOPD patients were randomly divided into 3 groups, numbered A, B and C and treated with ODN. Oxygen flow of groups A, B and C was 4-5, 6-7 and 8-9 L/min, respectively. Heart rate, respiratory rate, SpO2, SaO2, PaO2, PaCO2 and pH were recorded before ODN and 30 minutes after ODN. Statistical differences of data before or after ODN were analyzed by analysis of variance and F-test, whereas data before and after ODN were tested by paired t test. RESULTS: There was no significant difference of heart rate, respiratory rate, SpO2, PaO2, PaCO2, SaO2 and pH among 3 groups before ODN or after ODN. The heart rate was increased in all groups after ODN. But significant increase was only present in groups A and C but not in group B. SaO2 was significantly increased in group C after ODN but no statistical difference was observed between before and after ODN in groups A and B. There was no significant change in respiratory rate, SpO2, PaO2, PaCO2, SaO2 and pH between before and after ODN in all groups. CONCLUSIONS: Optimal oxygen flow in ODN-treating AECOPD patients may be 6-7 L/min.


Asunto(s)
Análisis de los Gases de la Sangre/métodos , Nebulizadores y Vaporizadores , Oxígeno/administración & dosificación , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Enfermedad Pulmonar Obstructiva Crónica/terapia , Enfermedad Aguda , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Oxígeno/sangre , Respiración con Presión Positiva/métodos , Enfermedad Pulmonar Obstructiva Crónica/sangre , Resultado del Tratamiento
3.
Zhonghua Liu Xing Bing Xue Za Zhi ; 34(3): 214-7, 2013 Mar.
Artículo en Chino | MEDLINE | ID: mdl-23759223

RESUMEN

OBJECTIVE: To investigate the risk of HBV infection among the spouses of hepatitis B virus surface antigen (HBsAg) carriers and to provide a reference for developing strategies on hepatitis B control and prevention. METHODS: A case-control study including HBsAg carriers aged 20 - 45 years-old from the nationwide sero-epidemiological survey for Hepatitis B in both Guangdong and Jiangxi provinces in 2006, together with their spouses were selected as case group, while. HBsAg negative persons and their spouses were among the control groups, under the same residential areas, gender, age and age of marriage to the HBsAg carriers. Questionnaire survey and hepatitis B serological markers detection were carried out, together with the HBV genotype detection among the HBsAg positive couples between husband and wife by PCR. RESULTS: Among the spouses of HBsAg carriers, the positive rate of HBsAg was 13.21%, while the rate was 6.29% for the spouse of HBsAg negative population, with difference statistically significant (χ² = 4.23, P < 0.05). HBsAg positive rate among spouses of the case group was higher than that in the control group. Among the spouses of HBsAg carriers, the HBsAg rate was positively correlated with the age of marriage, frequency of sexual intercourse and condom use. There were 21 pairs of HBsAg carriers between husband and wife, and HBV were isolated among 13 pairs, and there were 11 pairs carrying the same HBV genotype, accounting for 84.62%. HBV genotypes would include 8 pairs of type B and 3 pairs of type C. However, only 2 pairs were infected with different HBV genotype. CONCLUSION: High risks of HBV infection existed in the spouses of HBsAg carriers. It was important to ask the HBsAg carriers to take the initiative in informing their spouses, and carrying out the appropriate measures, such as safe sex or timely hepatitis B vaccination for the spouse of HBsAg carriers etc., so as to reduce the HBV transmission between husband and wife.


Asunto(s)
Portador Sano , Hepatitis B/epidemiología , Esposos , Adulto , Portador Sano/sangre , Portador Sano/virología , Estudios de Casos y Controles , Femenino , Genotipo , Hepatitis B/virología , Antígenos de Superficie de la Hepatitis B/sangre , Virus de la Hepatitis B/genética , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven
4.
Zhonghua Liu Xing Bing Xue Za Zhi ; 28(9): 872-4, 2007 Sep.
Artículo en Chino | MEDLINE | ID: mdl-18251270

RESUMEN

OBJECTIVE: To better understand the proportions of reported hepatitis B cases in pilot surveillance cites through investigation and laboratory testing. METHODS: To confirm the reported cases of hepatitis B by collecting blood specimen and laboratory testing on HBsAg, IgM of Anti-HBc, Anti-HAV in 18 pilot surveillance counties. RESULTS: Among 2858 cases of hepatitis B reported in 2006, 23.97% of them were reported as suspected acute cases, 14.87% as acute cases, 20.33% as suspected chronic cases, 34.67% as chronic cases, 4.09% as cirrhosis and 2.06% as HCC. Among 1681 reported hepatitis B cases confirmed by laboratory testing, results showed that 24.16% of them were diagnosed as acute hepatitis B, but only 15.37% were confirmed as acute hepatitis B. Although the proportion confirmed as hepatitis B kept consistent as before, misclassification was found. CONCLUSION: In current surveillance system, reported hepatitis B cases were mainly chronic, only up to one third belonged to acute hepatitis B. The reported incidence of hepatitis B did not reflect the real incidence due to misclassification. To better define the burden on hepatitis B disease, it was necessary and urgent to revise the diagnostic criteria and to conduct surveillance on hepatitis B, under separate reporting categories which including acute and chronic cases of the disease.


Asunto(s)
Hepatitis B/epidemiología , Vigilancia de la Población , China/epidemiología , Hepatitis B/diagnóstico , Anticuerpos contra la Hepatitis B/sangre , Humanos , Incidencia , Proyectos Piloto
5.
Biomed Environ Sci ; 15(3): 196-202, 2002 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12500659

RESUMEN

OBJECTIVE: To study the relationship between micronutrient supplementation and children growth. METHODS: A double-blind, placebo-controlled trial was conducted in 156 growth retarded preschool children. They were randomly assigned to five groups: supplemental control (S-control, n = 28), zinc supplementation (+Zn, 3.5 mg Zn/day, n = 34), zinc and calcium supplementation (+ZnCa, 3.5 mg Zn + 250 mg Ca/day, n = 37), zinc and calcium and vitamin A supplementation (+ZnCaVA, 3.5 mg Zn + 250 mg Ca + 200 g VA/day, n = 28), Calcium, and vitamin A supplementation (+CaVA, 250 mg Ca + 200 g VA/day, n = 29). Another 34 children with normal height were selected as normal control (N-control). Supplementation continued for twelve months. RESULTS: The height gain in +Zn group (7.84 cm per year) and +ZnCa group (7.70 cm per year) was significantly higher than that in S-control group (6.74 cm per year, P < 0.05); The weight gain in +ZnCaVA group (2.55 kg per year) and +CaVA group (2.57 kg per year) was also significantly higher than that in S-control group (2.19 kg per year, P < 0.05); The average days of illness in each supplementation group were lower than that in S-control (13 days per year compared with 23 days per year). No significant difference was observed on bone age. CONCLUSION: Zinc and Zinc + Calcium supplementation can improve the height gain, and vitamin A can improve weight gain in growth retarded preschool children, but do not affect the maturity of bone. Micronutrient supplementation can lower the morbidity of these children.


Asunto(s)
Desarrollo Infantil , Suplementos Dietéticos , Trastornos del Crecimiento/dietoterapia , Estado Nutricional , Estatura , Calcio/administración & dosificación , Calcio/farmacología , Preescolar , China , Femenino , Humanos , Masculino , Vitamina A/administración & dosificación , Vitamina A/farmacología , Aumento de Peso , Zinc/administración & dosificación , Zinc/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA